Alnylam Pharmaceuticals (ALNY) Current Deferred Revenue (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Current Deferred Revenue came in at $4.0 million in Q2 2026, down 73.38% YoY from $15.1 million in Q2 2025, and up 24.93% on a QoQ basis from $3.2 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Current Deferred Revenue (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Current Deferred Revenue data on file, last reported at $4.0 million in Q2 2026.
- Quarterly Current Deferred Revenue fell 73.38% year-over-year to $4.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $4.0 million (down 73.38% YoY) and the FY2025 annual result came in at $4.8 million, down 91.27% from the prior year.
- Current Deferred Revenue grew to $4.0 million in Q2 2026, from $3.2 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $290.8 million in Q4 2023 to a low of $2.5 million in Q3 2025.
- A 5-year average of $78.6 million and a median of $62.2 million in 2024 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2024 — Current Deferred Revenue jumped 114.7% — and 2025, when it tumbled 96.42%.
- Tracing ALNY's Current Deferred Revenue over 5 years: stood at $235.5 million in 2022, then rose by 23.45% to $290.8 million in 2023, then sank by 80.92% to $55.5 million in 2024, then tumbled by 91.27% to $4.8 million in 2025, then dropped by 17.15% to $4.0 million in 2026.
- The last three Current Deferred Revenue figures came in at $4.0 million (Q2 2026), $3.2 million (Q1 2026), and $4.8 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.01 Mn |
| Mar 31, 2026 | 3.21 Mn |
| Dec 31, 2025 | 4.85 Mn |
| Sep 30, 2025 | 2.54 Mn |
| Jun 30, 2025 | 15.08 Mn |
| Mar 31, 2025 | 28.16 Mn |
| Dec 31, 2024 | 55.48 Mn |
| Sep 30, 2024 | 71.03 Mn |
| Jun 30, 2024 | 69.01 Mn |
| Mar 31, 2024 | 76.85 Mn |
| Dec 31, 2023 | 102.75 Mn |
| Sep 30, 2023 | 77.14 Mn |
| Jun 30, 2023 | 54.64 Mn |
| Mar 31, 2023 | 35.79 Mn |
| Dec 31, 2022 | 42.11 Mn |
| Sep 30, 2022 | 73.63 Mn |
| Jun 30, 2022 | 114.29 Mn |
| Mar 31, 2022 | 131.84 Mn |
| Dec 31, 2021 | 88.63 Mn |
| Sep 30, 2021 | 76.45 Mn |